Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Longboard Pharmaceuticals ( (LBPH) ) has issued an announcement.
Lundbeck is set to acquire Longboard Pharmaceuticals in a strategic deal valued at approximately $2.6 billion, aiming to bolster its neuroscience pipeline. This acquisition will enhance Lundbeck’s presence in neuro-rare conditions, particularly with Longboard’s bexicaserin, a promising treatment for Developmental and Epileptic Encephalopathies (DEEs). The agreement offers Longboard shareholders $60 per share, a significant premium, and is expected to close by the fourth quarter of 2024, subject to regulatory approvals.
Learn more about LBPH stock on TipRanks’ Stock Analysis page.